Frequently Asked Questions
NOTE: Nu-V3 is pre-regulatory clearance and anticipates full market entry in the United States, early 2021, followed by Europe, Japan, Latin America and Canada.
Information contained on this website is intended to educate the viewer about Nu-V3, how it works, our commitment to long term benefit for our patients and the results collected to date through IRB approved clinical trial. Any use of Nu-V3, the Nu-V3 treatment program and initiatives such as The H.O.P.E. Initiative are for this purpose and are conducted under strict FDA guidelines and IRB approval.
